Pharmaceuticals
Huahui Health and BeOne Medicines Enter into a Global Exclusive Option, License and Collaboration Agreement for Innovative Oncology Drug HH160
BEIJING, April 30, 2026 /PRNewswire/ -- Huahui Health today announced that it has entered into a global exclusive option, license and collaboration agreement with BeOne Medicines for HH160, a novel trispecific antibody in oncology immunotherapy. Under the agreement, BeOne Medicines is granted an ...
2026-04-30 16:28
5486
Formosa Pharmaceuticals and Singapore Eye Research Institute (SERI) Partner to Advance Novel Ophthalmic Formulations for Corneal Diseases
SINGAPORE and TAIPEI, April 30, 2026 /PRNewswire/ -- Formosa Pharmaceuticals, Inc. ("Formosa", 6838.TW) and the Singapore Eye Research Institute ("SERI") are pleased to announce a strategic research collaboration to develop next-generation ophthalmic formulations. This partnership will leverage ...
2026-04-30 14:30
5419
New Classification System of Malocclusions Published in the Journal of Aligner Orthodontics (JAO) by Prof. Gang Shen's Team
SHANGHAI, April 30, 2026 /PRNewswire/ -- A seminal research paper titled "A New Classification System for Malocclusions with Facial Convexity"has been officially published in the 2026 Volume 1 issue of the Journal of Aligner Orthodontics (JAO). This article, authored by Professor Gang Shen and hi...
2026-04-30 13:33
4539
2026 ESMO GC | Mabwell to Present Latest Clinical Data on 9MW2821 for Cervical Cancer in Oral and Poster Presentations
SHANGHAI, April 30, 2026 /PRNewswire/ -- Mabwell (688062.SH, 02493.HK), an innovation-driven biopharmaceutical company with a fully integrated industry chain, today announced that two latest clinical study results of its novel Nectin‑4 targeting ADC (R&D code: 9MW2821) in cervical cancer will be ...
2026-04-30 12:26
4949
ACROBiosystems and SeromYx Systems Announce Strategic Collaboration on Comprehensive Functional Profiling of Anti-CD20 Monoclonal Antibodies
TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, has entered into a research collaboration with SeromYx Systems, specializing in advanced immunology technologies. The partne...
2026-04-30 08:30
5352
Ascletis to Present Data on Multiple Programs at the American Diabetes Association's 2026 Scientific Sessions
HONG KONG, April 30, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") announces today poster presentations highlighting multiple programs at the American Diabetes Association's (ADA's) 2026 Scientific Sessions, taking place June 5–8, 2026 in New Orleans, Louisiana. The presentat...
2026-04-30 08:10
4686
ACROBiosystems collaborates with Carterra, accelerating large-scale characterization of potential drug candidates
TOKYO and NEWARK, Del., April 30, 2026 /PRNewswire/ -- ACROBiosystems, a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries, announces its collaboration with Carterra, a company focused on innovative technologies designed to accelerate the discovery...
2026-04-30 08:00
4311
OPTIMAL-PSMA Trial of TLX597-Tx Next Generation RLT Presented at IPCS 2026 Highlighting Therapeutic Potential in Prostate Cancer
* TLX597-Tx is a PSMA[1]-targeting small molecule radioligand therapy (RLT) candidate, designed to improve quality-of-life and efficacy in earlier-stage prostate cancer. * OPTIMAL-PSMA[2] initial dosimetry data demonstrate low salivary gland and kidney uptake, supporting dose intensification....
2026-04-30 05:00
5654
WuXi Biologics Releases 2025 Sustainability Report, Advancing Sustainable Growth and Improving Healthcare Access
* Contributing to the United Nations Sustainable Development Goals, driving equitable access to healthcare through technology and innovation * Enhancing governance transparency and effectiveness to create long-term value for all stakeholders * Empowering employees and fostering shared value ...
2026-04-29 20:30
4843
ESG | HitGen Releases 2025 Sustainability Report
CHENGDU, China, April 29, 2026 /PRNewswire/ -- Shanghai Stock Exchange listed company HitGen Inc. ("HitGen", SSE: 688222.SH) released its 2025 Sustainability Report on April 29, 2026. This report is the second sustainability report of HitGen, aiming to present the Company's philosophies and polic...
2026-04-29 19:00
3819
LTS Expands CDMO Portfolio with Ophthalmic Drug Delivery Solutions
ANDERNACH, Germany, April 29, 2026 /PRNewswire/ -- LTS LOHMANN Therapie-Systeme AG ("LTS"), a leading pharmaceutical technology company specializing in advanced drug delivery systems, today announced the expansion of its service portfolio to include CDMO services for ophthalmic drug delivery solu...
2026-04-29 19:00
3356
China's Yangtze River Pharmaceutical Group Expands Global Footprint as Quality Drives Growth
TAIZHOU, China, April 29, 2026 /PRNewswire/ -- In 2025, Yangtze River Pharmaceutical Group (YRPG) made significant progress in both global growth and quality initiatives. The company's international revenue increased more than fourfold year over year, while the number of its global partners more ...
2026-04-29 18:57
2631
European Commission (EC) Approves Henlius and Organon's POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe
SHANGHAI, April 29, 2026 /PRNewswire/ -- Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar ...
2026-04-29 18:08
3655
Insilico's Rentosertib Inhalation Solution Receives IND Clearance for the World's First AI-Driven Candidate to Enter Direct-to-Lung Clinical Study
* Following positive Phase IIa results for oral Rentosertib in GENESIS-IPF with good tolerability, a favorable PK profile, and dose-dependent efficacy improvements, the inhalation solution has received IND clearance from the CDE. * The inhalation solution is designed for targeted lung delivery...
2026-04-29 09:00
4452
Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
MUMBAI, India, April 28, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026. Consolidated...
2026-04-29 03:51
4421
ACROBiosystems Wins CiteAb Award, Gaining Worldwide Recognition
SAN DIEGO and NEWARK, Del., April 28, 2026 /PRNewswire/ -- Recently, ACROBiosystems was honored as a "Protein Supplier to Watch in Cancer Research in 2026" at the CiteAb Awards. CiteAb accelerates scientific research by providing a search engine and data services, and its awards leverage high-qu...
2026-04-28 23:00
4135
Natural Field Releases Research Findings on NFTriSolve® Co-Loading Liposome Formula
XI'AN, China, April 28, 2026 /PRNewswire/ -- Natural Field announced that the latest research and development breakthrough of the NFTriSolve® co-loading liposome technology has been achieved. Through a comparison of different formulations and processes in a zebrafish experiment, the research resu...
2026-04-28 22:59
4674
Fosun Pharma Announces Q1 2026 Results: Net Profit Attributable to Shareholders After Deducting Non-Recurring Gains and Losses Increased by 21.96% YoY, With Strong Pipeline Execution
SHANGHAI, April 28, 2026 /PRNewswire/ -- On 28 April, Fosun Pharma ("the Company", stock code: 600196.SH; 02196.HK) announced its results for the first quarter of 2026 (the reporting period). During the reporting period, the Company achieved a total revenue of RMB 10,073 million, representing a ...
2026-04-28 22:54
6494
ACROBiosystems Showcases AI-Driven Innovation at AACR 2026, Empowering Next-Generation Biologics Discovery
SAN DIEGO and NEWARK, N.J., April 28, 2026 /PRNewswire/ -- From April 17 to 22, 2026, ACROBiosystems—a company dedicated to being a cornerstone of the global biopharmaceutical and healthcare industries—presented its comprehensive, AI‑driven protein solutions at the American Association for Cancer...
2026-04-28 22:00
5110
C-Ray Therapeutics Receives FDA Acceptance of Type II Drug Master File for Copper-64 (Cu-64)
DMF No. 43568 is now active and available for reference in global IND and NDA submissions CHENGDU, China, April 28, 2026 /PRNewswire/ -- C-Ray Therapeutics (Chengdu) Co., Ltd., today announced that its Type II Drug Master File (DMF) for COPPER [64Cu] CHLORIDE FOR RADIOLABELLING has been listed a...
2026-04-28 21:11
2970
Week's Top Stories
Most Reposted
Asia Pacific Travellers Seek Familiarity, Practicality, Flexibility Amid Shifting Global Dynamics: Visa Report
[Picked up by 326 media titles]
2026-06-16 10:00
Visa and Mintoak Join Forces to Bring Merchant SaaS Capabilities to Acquirers Across Asia Pacific
[Picked up by 313 media titles]
2026-06-17 11:00NOVVA Group acquires 120 MWp Philippines solar project, anchoring its AI-era power platform in Southeast Asia
[Picked up by 299 media titles]
2026-06-19 11:12
MediThinQ and Synovis Micro Companies Alliance, Inc. Announce Strategic Global Distribution Agreement to Redefine Microsurgery with the SHIYA 3D Visualization Platform
[Picked up by 297 media titles]
2026-06-18 22:01
Affinidi and CardInfoLink Put the Missing Trust Layer for AI Agents into Production
[Picked up by 297 media titles]
2026-06-19 09:00
Most Read
Asia Pacific Travellers Seek Familiarity, Practicality, Flexibility Amid Shifting Global Dynamics: Visa Report
2026-06-16 10:00
6651
All Eyes on Korea: CSOP KOSPI 200 ETF (3121.HK) to List on HKEX Tomorrow
2026-06-17 21:17
4866
